работа банка с юридическими лицами дипломная работа
Главное меню:
Интересное
работа банка с юридическими лицами дипломная работа, XYWAV for Idiopathic Hypersomnia | XYWAV® IH, FDA-Approved Treatment for Idiopathic Hypersomnia | XYWAV HCP, FDA Approves First-Ever Treatment for Idiopathic Hypersomnia - Sleep Review, List of 7 Idiopathic Hypersomnia Medications Compared, How Xywav Works, And Other Questions Answered - GoodRx, Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing , XYWAV for Narcolepsy & Idiopathic Hypersomnia | XYWAV®.
CategoryMedicationsMechanism of ActionCommon IndicationsStimulantsModafinil, ArmodafinilPromotes wakefulness through dopamine pathwaysNarcolepsy, Sleep Apnea, Shift Work Disorder MethylphenidateCNS stimulant that increases dopamine and norepinephrineAttention-Deficit/Hyperactivity Disorder (ADHD), Narcolepsy Amphetamine saltsEnhances release of dopamine and norepinephrineADHD, NarcolepsyNon-Stimulant Wakefulness AgentsSolriamfetolDopamine and norepinephrine reuptake inhibitorNarcolepsy, Sleep Apnea PitolisantHistamine H3 receptor antagonistNarcolepsyOther MedicationsSodium oxybateGABA receptor modulator, improves sleep architectureNarcolepsy with Cataplexy AntidepressantsModulate serotonin and norepinephrineDepression-related EDS, Excessive daytime sleepiness Sleep inertia Severe grogginess or confusion when waking up regardless of how much sleep you get or how many alarms you set—feeling disoriented, irritable, or even clumsy when waking up and for hours afterwards, The safety and effectiveness of XYWAV for the treatment of cataplexy or excessive daytime sleepiness in pediatric patients 7 years of age and older with narcolepsy have been established..
This milestone marks the second FDA approval for Xywav since it was first approved in July 2020 for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy. Xywav can be administered as a twice- or once-nightly regimen for the treatment of idiopathic hypersomnia in adults., Idiopathic hypersomnia is a debilitating neurologic sleep disorder characterized by chronic excessive daytime sleepiness, making it difficult to stay awake and alert during the day. People with idiopathic hypersomnia can sleep for adequate amounts of time each night but still feel excessively sleepy during the day., Xywav was originally FDA-approved in 2002 to treat excessive daytime sleepiness (EDS) and cataplexy (sudden muscle weakness triggered by strong emotions) in people at least 7 years old who have narcolepsy. It became FDA-approved for IH in adults in 2021. Xywav is unique because it’s the only medication that’s specifically FDA-approved for IH., Xywav is the only low-sodium oxybate approved by the U.S. Food and Drug Administration for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy and for adults with idiopathic hypersomnia. The Xywav label recommends a nightly dose of 6-9 grams per night., Learn about an FDA-approved treatment for cataplexy and/or excessive daytime sleepiness in narcolepsy and for idiopathic hypersomnia (IH) in adults. See full Prescribing Information & BOXED Warning about serious side effects, CNS depression, and misuse and abuse., Management of excessive daytime sleepiness (EDS) includes both pharmacologic and nonpharmacologic options, depending on its underlying cause..